DrugDashboards

Depo-Medrol

methylprednisolone acetate · METHYLPREDNISOLONE ACETATE 80 mg/mL · Injection, Suspension · Intralesional; Intramuscular; Intrasynovial; Soft Tissue · Pharmacia & Upjohn Company LLC

NDC 00009-0306-02 · 5 mL in 1 VIAL, MULTI-DOSE · NDA · View full market →

The short version

9 companies supply this market — a reasonable cushion if one runs into trouble. The brand price is down 22% over the past year, to $10.80 per mL. It is in shortage right now — FDA lists the reason as “other”. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$10.80per MLinvoice-surveyed acquisition cost · Apr 23, 2025
  • Medicare Part B pays (ASP+6%)$0.1170per billing unit (1 MG)HCPCS J1010 · Jul 1, 2026
  • Part D plans paid (avg)$15.58per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal ceiling (Big4)$36.14per package of 5MLPfizer Inc. · Jan 1, 2026

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$10.00$20.00Nov 2013Apr 2025$10.80
38 price points · per ML · last surveyed Invalid DateSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$98.69
Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 1 MG
$0.117
HCPCS J1010 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$283,711
40,910 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

35● Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • in shortage now+25
  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.5%chance of a new FDA shortage posting for methylprednisolone acetate (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $27.50 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA011757
TE code
AB
Approval date
Jan 1, 1982
Patents / exclusivity
None on file

Shortage history

  • In shortage now — Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)Jun 16, 2022
    Other
    month 51 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)Dec 15, 2021
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)Dec 15, 2021
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)Dec 15, 2021
    Other
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)Dec 15, 2021
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)Dec 15, 2021
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)Dec 15, 2021
    Demand increase for the drug
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)Dec 15, 2021
    Other
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)Dec 15, 2021
    Demand increase for the drug
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)Dec 15, 2021
    Other
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)Dec 15, 2021
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)Dec 15, 2021
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)Dec 15, 2021
    Other
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)Dec 15, 2021
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)Dec 15, 2021
    Shortage of an active ingredient
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)Dec 15, 2021
    Shortage of an active ingredient
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)Dec 15, 2021
    Demand increase for the drug
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)Dec 15, 2021
    Other
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)Dec 15, 2021
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months
  • In shortage now — Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)Dec 15, 2021
    Shortage of an active ingredient
    month 57 — 3× the typical 20-month injectable shortage · model puts 27% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of methylprednisolone acetate (Injection, Suspension)

LabelerStrengthFirst seenLast seen
A-S Medication SolutionsMETHYLPREDNISOLONE ACETATE 40 mg/mLJul 15, 2026Sep 3, 2026
Amneal Pharmaceuticals LLCMETHYLPREDNISOLONE ACETATE 40 mg/mLJul 15, 2026Sep 3, 2026
Pharmacia & Upjohn Company LLCMETHYLPREDNISOLONE ACETATE 40 mg/mLJul 15, 2026Sep 3, 2026
Pharmacia & Upjohn Company LLCMETHYLPREDNISOLONE ACETATE 80 mg/mLJul 15, 2026Sep 3, 2026
Amneal Pharmaceuticals NY LLCMETHYLPREDNISOLONE ACETATE 40 mg/mLJul 15, 2026Sep 2, 2026
Amneal Pharmaceuticals NY LLCMETHYLPREDNISOLONE ACETATE 80 mg/mLJul 15, 2026Sep 2, 2026
Asclemed USA, Inc.METHYLPREDNISOLONE ACETATE 80 mg/mLJul 15, 2026Sep 2, 2026
Caplin Steriles LimitedMETHYLPREDNISOLONE ACETATE 80 mg/mLJul 15, 2026Sep 2, 2026
Caplin Steriles LimitedMETHYLPREDNISOLONE ACETATE 40 mg/mLJul 15, 2026Sep 2, 2026
Eugia US LLCMETHYLPREDNISOLONE ACETATE 80 mg/mLJul 15, 2026Sep 2, 2026
Eugia US LLCMETHYLPREDNISOLONE ACETATE 40 mg/mLJul 15, 2026Sep 2, 2026
Pharmacia & Upjohn Company LLCMETHYLPREDNISOLONE ACETATE 20 mg/mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsMETHYLPREDNISOLONE ACETATE 40 mg/mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsMETHYLPREDNISOLONE ACETATE 80 mg/mLJul 15, 2026Sep 2, 2026
A-S Medication SolutionsMETHYLPREDNISOLONE ACETATE 80 mg/mLJul 15, 2026Aug 31, 2026
Sportpharm LLCMETHYLPREDNISOLONE ACETATE 40 mg/mLJul 15, 2026Aug 31, 2026
Amneal Pharmaceuticals LLCMETHYLPREDNISOLONE ACETATE 80 mg/mLJul 15, 2026Aug 28, 2026
Asclemed USA, Inc.METHYLPREDNISOLONE ACETATE 40 mg/mLJul 15, 2026Aug 28, 2026
Endo USA, Inc.METHYLPREDNISOLONE ACETATE 40 mg/mLJul 15, 2026Jul 31, 2026
Endo USA, Inc.METHYLPREDNISOLONE ACETATE 80 mg/mLJul 15, 2026Jul 29, 2026
Sandoz Inc.METHYLPREDNISOLONE ACETATE 40 mg/mLJul 15, 2026Jul 29, 2026
Sandoz Inc.METHYLPREDNISOLONE ACETATE 80 mg/mLJul 15, 2026Jul 29, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Depo-Medrol — NDC 00009-0306-02," retrieved September 3, 2026, https://drugdashboards.com/drug/00009030602.

Free to cite with attribution — see how the data is put together.